SCHEMBL23919005

SCHEMBL23919005

CC(C)(C)CCN1CCCC(C(C)(C)C)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 2/20 0.39
CYP2D6 P10635 3/20 0.33
CHRM2 P08172 3/20 0.33
CHRM1 P11229 3/20 0.33
CHRM3 P20309 3/20 0.33
KCNH2 Q12809 2/20 0.33
HTR1A P08908 2/20 0.33
DRD2 P14416 2/20 0.33
CHRM4 P08173 2/20 0.33
CHRM5 P08912 2/20 0.33
GRIN2D O15399 1/20 0.33
GRIN3B O60391 1/20 0.33
HRH1 P35367 1/20 0.33
GRIN1 Q05586 1/20 0.33
GRIN2A Q12879 1/20 0.33
GRIN2B Q13224 1/20 0.33
GRIN2C Q14957 1/20 0.33
GRIN3A Q8TCU5 1/20 0.33
CYP3A4 P08684 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6784201 0.83 DRD2 (0.47) DRD2DRD1DRD4DRD5DRD3
SCHEMBL19798808 0.81 HTR7 (0.39) HTR7DRD2DRD1DRD4DRD5
SCHEMBL12424238 0.81 HTR7 (0.36) HTR7DRD2DRD1DRD4DRD5
SCHEMBL19798824 0.81 ALDH1A1 (0.39) HTR7DRD2DRD1DRD4DRD5
SCHEMBL23919003 0.81 ALDH1A1 (0.36) HTR7HTTL3MBTL1
SCHEMBL20805234 0.80 CACNA1H (0.34)
SCHEMBL12449640 0.79 HRH3 (0.45) MAPT
SCHEMBL12721 0.79 HRH3 (0.45) MAPT
SCHEMBL12449643 0.79 HRH3 (0.45) MAPT
SCHEMBL12062327 0.79 CARM1 (0.52) HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858940-B2 Selective modulators of mutant LRRK2 proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2024-01-02 US disclosed
US-20230097358-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2023-03-30 US disclosed
US-20210315896-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2021-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210315896-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE LRRK2, CRBN, MDM2 HTR7 1873/4885CYP2D6 3985/4885CHRM2 3312/4885
US-20230097358-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE LRRK2, CRBN, MDM2 HTR7 1873/4885CYP2D6 3985/4885CHRM2 3312/4885
US-11858940-B2 Selective modulators of mutant LRRK2 proteolysis and associated methods of use LRRK2, ADRM1, CRBN HTR7 2325/4885CYP2D6 4738/4885CHRM2 3182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.